| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Detecting plasma SHOX2, HOXA9, SEPTIN9, and RASSF1A methylation and circulating cancer cells for cholangiocarcinoma clinical diagnosis and monitoring
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jing Yu, Qiu-Chen Liu, Shuang-Yan Lu, Shun Wang and Hua Zhang |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Medical Talents of Wuhan Health and Family Planning Commission |
2017[51] |
| Medical Talents of Wuhan Hospital of Traditional Chinese and Western Medicine |
|
| Hubei Natural Science Foundation |
2023AFB1091 |
| Wuhan Medical Research Project |
WX23A36 |
|
| Corresponding Author |
Shun Wang, Department of Laboratory, Wuhan Chinese and Western Medicine Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 215 Zhongshan Road, Wuhan 430022, Hubei Province, China. wang_shun6688@sina.com |
| Key Words |
Cholangiocarcinoma; Methylation; Circulating cancer cells; Diagnosis; Prognosis |
| Core Tip |
This study first analyzed the clinical diagnosis and monitoring value of detecting plasma SHOX2, HOXA9, SEPTIN9, and RASSF1A methylation for cholangiocarcinoma (CCA). We determined that the four DNA plasma methylations exhibited 64.58% sensitivity and 94% specificity for detecting CCA. The hazard ratio of prognosis for the risk of CCA risk was identified using the Circulating tumor cells (CTCs) count, tumor stage, methylation, and carbohydrate antigen 19-9 (CA199) levels as independent prognostic factors. We developed a predictive nomogram for CCA overall survival, age, stage, CTCs, methylation, and CA199, with a C-index of 0.705 (95%CI: 0.605-0.805). This model evaluates risk factors. |
| Publish Date |
2025-03-25 16:19 |
| Citation |
<p>Yu J, Liu QC, Lu SY, Wang S, Zhang H. Detecting plasma SHOX2, HOXA9, SEPTIN9, and RASSF1A methylation and circulating cancer cells for cholangiocarcinoma clinical diagnosis and monitoring. <i>World J Gastrointest Oncol</i> 2025; 17(4): 104253</p> |
| URL |
https://www.wjgnet.com/1948-5204/full/v17/i4/104253.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v17.i4.104253 |
